Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson's Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)Business Wire • 06/20/23
Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record PacePRNewsWire • 06/08/23
Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/11/23
Wall Street Analysts See a 213.78% Upside in Annovis Bio, Inc. (ANVS): Can the Stock Really Move This High?Zacks Investment Research • 05/04/23
Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick HumansGlobeNewsWire • 04/27/23
ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCASTPRNewsWire • 04/20/23
ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCASTPRNewsWire • 04/19/23
Wall Street Analysts Think Annovis Bio, Inc. (ANVS) Could Surge 190.96%: Read This Before Placing a BetZacks Investment Research • 04/18/23
ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMSPRNewsWire • 04/13/23
Annovis Bio, Inc. (ANVS) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 04/07/23
ANNOVIS BIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEPRNewsWire • 04/03/23
Annovis And Buntanetap: Asymmetric Risk/Reward Ahead Of Parkinson's Data ReadoutSeeking Alpha • 03/30/23
Here's Why Momentum in Annovis Bio, Inc. (ANVS) Should Keep goingZacks Investment Research • 03/30/23
ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASESPRNewsWire • 03/22/23
Is Annovis Bio (ANVS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 02/17/23
Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 152.89%: Here's is How to TradeZacks Investment Research • 02/17/23
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's DiseasePRNewsWire • 02/08/23
Does Annovis Bio, Inc. (ANVS) Have the Potential to Rally 178.45% as Wall Street Analysts Expect?Zacks Investment Research • 02/01/23
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental IllnessesPRNewsWire • 02/01/23
ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASEPRNewsWire • 01/25/23